Shefer S, Salen G, Nguyen L, Batta A K, Packin V, Tint G S, Hauser S
Department of Medicine, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark 07103.
J Clin Invest. 1988 Dec;82(6):1833-9. doi: 10.1172/JCI113799.
The 7 alpha-hydroxylation of two cholesterol analogues, sitosterol and cholestanol, and their effect on the 7 alpha-hydroxylation of cholesterol were measured in rat and human hepatic microsomes. In untreated rat liver microsomes, the 7 alpha-hydroxylation of cholesterol was higher than that of cholestanol (1.4-fold) and sitosterol (30-fold). After removal of endogenous sterols from the microsomes by acetone treatment, the 7 alpha-hydroxylation of cholesterol was similar to that of cholestanol and only fourfold higher than that of sitosterol. Cholestanol and sitosterol competitively inhibited cholesterol 7 alpha-hydroxylase in both rat and human liver microsomes, with cholestanol the more potent inhibitor. Patients with sitosterolemia with xanthomatosis, who have elevated microsomal cholestanol and sitosterol, showed reduced cholesterol 7 alpha-hydroxylase activity relative to the activity in control subjects (13.9 and 14.7 vs. 20.3 +/- 0.9 pmol/nmol P-450 per min, P less than 0.01). Enzyme activity in these patients was 40% higher when measured in microsomes from which competing sterols had been removed. Ileal bypass surgery in one sitosterolemic patient decreased plasma cholestanol and sitosterol concentrations and resulted in a 30% increase in hepatic microsomal cholesterol 7 alpha-hydroxylase activity. Cholesterol 7 alpha-hydroxylase appears to have a specific apolar binding site for the side chain of cholesterol and is affected by the presence of cholestanol and sitosterol in the microsomal substrate pool. Reduced bile acid synthesis in sitosterolemia with xanthomatosis may be related to the inhibition of cholesterol 7 alpha-hydroxylase activity by endogenous cholesterol analogues.
在大鼠和人肝微粒体中测定了两种胆固醇类似物,即谷甾醇和胆甾烷醇的7α-羟基化作用及其对胆固醇7α-羟基化作用的影响。在未经处理的大鼠肝微粒体中,胆固醇的7α-羟基化作用高于胆甾烷醇(1.4倍)和谷甾醇(30倍)。用丙酮处理微粒体以去除内源性甾醇后,胆固醇的7α-羟基化作用与胆甾烷醇相似,仅比谷甾醇高4倍。胆甾烷醇和谷甾醇在大鼠和人肝微粒体中均竞争性抑制胆固醇7α-羟化酶,胆甾烷醇是更有效的抑制剂。患有黄瘤病的谷甾醇血症患者,其微粒体胆甾烷醇和谷甾醇升高,相对于对照受试者的活性,其胆固醇7α-羟化酶活性降低(分别为13.9和14.7 vs. 20.3±0.9 pmol/nmol P-450每分钟,P<0.01)。当在去除了竞争性甾醇的微粒体中测量时,这些患者的酶活性高40%。一名谷甾醇血症患者进行回肠旁路手术后,血浆胆甾烷醇和谷甾醇浓度降低,肝微粒体胆固醇7α-羟化酶活性增加30%。胆固醇7α-羟化酶似乎对胆固醇侧链有一个特定的非极性结合位点,并受微粒体底物池中胆甾烷醇和谷甾醇的存在影响。患有黄瘤病的谷甾醇血症中胆汁酸合成减少可能与内源性胆固醇类似物对胆固醇7α-羟化酶活性的抑制有关。